William RAOUL
  • E-mail :[email]
  • Phone : +33 2 47 36 62 67
  • Location : Tours, France
Last update 2015-02-23 14:46:07.978

William RAOUL PhD, CR1 INSERM

Course and current status

Professional experience

Since 01/10/2013 : Researcher CR1, UMR 7292 (Tours, France). Fields : Therapeutic Monoclonal antibodies, Oncology, Pharmacokinetics and Modeling

2012-2013 : Researcher CR2, Inserm UMR S 968, Institut de la Vision (Paris, France). Fields : Age-related macular degeneration, Choroidal neovascularization and Inflammation

2009-2012: Researcher CR2, Inserm UMR S 872, Centre de Recherche des Cordeliers (Paris, France). Fields : Age-related macular degeneration, Inflammation and Chemokines

2006-2009 : Post-doctoral position in Ophtalmology, Inserm UMR S 872, Centre de Recherche des Cordeliers (Paris, France). Fields : Age-related macular degeneration and Therapeutic tools

Training

2001-2005 : PhD in Life and Health Sciences (Toxicology) with honours, Inserm U651, University of Paris XII (Créteil, France). Fields : Acute lung injury, Repair, Growth factors and Endothelial progenitors cells

2000-2001 : Master in Toxicology with honours, University of Paris V Descartes (Paris, France).  

Scientific summary

Research brief

The goal of the team is to understand how genetic and non-genetic variations translate into variable clinical responses to monoclonal antibodies in treated patients. Our general aim is to fill in the gap between genetics and clinical responses by establishing precise genotype-phenotype relationships for therapeutic antibody elimination and distribution (pharmacokinetics, PK) and mechanisms of action (pharmacodynamics, PD).

 

Methodologies used

• Pharmacokinetic and pharmacokinetic-pharmacodynamic (PK-PD) modelling of therapeutic monoclonal antibodies in human and in preclinical studies.

• Pharmacogenetics and genotype-phenotype relationships of therapeutic antibodies. In vitro and ex vivo cellular models, clinical studies in treated patients.

• Analysis of role of Fc-gamma-receptors and of FcRn in elimination and distribution of antibodies (pharmacokinetics) and in concentration-effect relationships in vivo (PK-PD).

Image d’exemple